GSK closes neuroscience R&D site in China and relocates it to USA

| By | China, GlaxoSmithKline, R&D

GlaxoSmithKline is closing its neuroscience research and development site in China and is moving it to the company’s hub in the Philadelphia which includes Conshohocken and Collegeville.

“Following a portfolio review and prioritization, GSK has decided to close its Neuroscience R&D Center in Shanghai and move key programs to its global R&D hub in Upper Providence, where they will benefit from co-location with other pipeline R&D programs,” said the company.

This represents a further reshuffle of GSK’s neuroscience division which used to be one of its key focuses. It is part of an ongoing reorganization of all of GSK’s R&D operations with the company dropping research into rare diseases and evaluating the benefits of around 30 of its other R&D programs.

GSK is also going through a major product revamp under the leadership of new CEO, Emma Walmsley. She is looking at adding both oncology and auto-inflammatory treatments to the company’s range of drugs. At present, most of its products are focused on treatments for HIV/infectious diseases and respiratory conditions.

SOURCE: montco
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.